Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE
First author：Pan, Yuesong Jing, Jing
Corresponding author：Wang, Yilong Wang, Yongjun
essential_information
- Person in charge：Pan, Yuesong Jing, Jing
- Data Sources： CHANCE
- Number of papers：OTHERS20190472
- Published time：2017-05-16
2017-05-16
Published articles
Journal：Neurology
Publication type: Original Research
IF(IF): 9.91
PMID: 28424269 Link To Pubmed Full text Download
Background And Purpose
Method
Data were derived from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial. The primary outcome was a new ischemic stroke. Safety outcomes included any bleeding and moderate to severe bleeding. Time course analyses were performed for the outcomes of both stroke and bleeding.
Conclusion
Clopidogrel-aspirin treatment may have a benefit of reducing stroke risk outweighing the potential risk of increased bleeding especially within the first 2 weeks compared with aspirin alone in patients with minor stroke or TIA.
Main results
A total of 145 (71.1%), 13 (6.4%), and 12 (5.9%) of 204 new ischemic strokes in the clopidogrel-aspirin group vs 223 (75.6%), 19 (6.4%), and 8 (2.7%) of 295 in the aspirin alone group occurred at the first, second, and third week, respectively. A total of 23 (38.3%), 15 (25.0%), and 9 (15.0%) of 60 bleeding cases in the clopidogrel-aspirin group vs 15 (36.6%), 8 (19.5%), and 3 (7.3%) of 41 in the aspirin alone group occurred at the first, second, and third week, respectively. Clopidogrel-aspirin treatment numerically reduced the risk of ischemic stroke within the first 2 weeks. From the 10th day, the number of any bleeding cases caused by dual antiplatelets outweighed that of new stroke reduced by dual antiplatelets.